This combination of Gliclazide, Metformin (SR), and Pioglitazone is used for the effective management of Type 2 Diabetes Mellitus, especially in patients who require multi-mechanism control of blood sugar levels. Gliclazide helps stimulate insulin release from the pancreas, Metformin (SR) reduces glucose production in the liver and improves insulin sensitivity, while Pioglitazone enhances the body’s response to insulin in peripheral tissues. Together, this triple therapy helps achieve better glycemic control, reduce insulin resistance, and minimize long-term complications associated with uncontrolled diabetes.
